Peyronie's Disease Knowledge And Practice Patterns Assessment: A Survey Of Urologists In The United States
Main Category: Urology / NephrologyArticle Date: 02 Jul 2008 - 5:00 PDT
ORLANDO, FL (UroToday.com) - In this presentation, Dr. John Mulhall, et al. examined practice patterns for the treatment of Peyronie's disease (PD) via a 46 point questionnaire sent to US urologists.
The questionnaire was returned by 639 urologists of whom 67% were private practice physicians and 33% were from academic centers. 76% practiced general urology and 40% considered themselves experts in sexual medicine. 78% said they were trained in PD management and 73% were trained in PD surgery during residency. First line treatment was oral agents in 72% with Vitamin E being the most common. Verapamil is used transdermally by 27% and via injection by 45%.
Interestingly, 79% perform surgery for PD with most, 70%, doing plications and 73% doing excision and grafting, and 61% doing implant surgery. This abstract is worth review to shed light on practice patterns in the US - some that will surprise the reader.
Presented by John P. Mulhall, MD, et al, at the Annual Meeting of the American Urological Association (AUA) - May 17 - 22, 2008. Orange County Convention Center - Orlando, Florida, USA.
Reported by UroToday.com Contributing Editor Michael J. Metro, MD
UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to: www.urotoday.com
Copyright © 2008 - UroToday
|
Please rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add to:
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
| Back to top | Back to front page | List of All Medical Articles |
| Privacy Policy | Terms and Conditions | © 2008 MediLexicon International Ltd |



